Subscribe (Free) to
Daily or Weekly Newsletters
Post a Job

Featured Jobs

ESOP Administration Consultant

Blue Ridge Associates
(Remote)

Blue Ridge Associates logo

Retirement Plan Administration Consultant

Blue Ridge Associates
(Remote)

Blue Ridge Associates logo

Relationship Manager – MEP/PEP

Benefit Plans Plus
(Remote / Saint Louis MO)

Benefit Plans Plus logo

Relationship Manager - DC

Daybright Financial
(Remote)

Daybright Financial logo

Retirement Plan Analyst - DC Plans

M2B Retirement Consulting LLC
(Remote / PA)

M2B Retirement Consulting LLC logo

Plan Consultant

BPAS
(Remote / Hybrid)

BPAS logo

Relationship Manager

Benefit Plans Plus
(Remote / Saint Louis MO)

Benefit Plans Plus logo

Senior Internal Sales Consultant

EPIC RPS
(Remote / Norwich NY)

EPIC RPS logo

Senior Retirement Plan Analyst - DC Plans

M2B Retirement Consulting LLC
(Remote / PA)

M2B Retirement Consulting LLC logo

Director of Regulatory Operations and Compliance

PCS Retirement
(Remote / PA)

PCS Retirement logo

View More Employee Benefits Jobs

Free Newsletters

“BenefitsLink continues to be the most valuable resource we have at the firm.”

-- An attorney subscriber

Mobile app icon
LinkedIn icon     Twitter icon     Facebook icon

FTC's 'Landmark' Settlement with Pharmacy Benefit Manager Express Scripts: Impact on Pharma
King & Spalding Link to more items from this source
Feb. 10, 2026

"Two remedial measures agreed to by ESI could particularly impact pharmaceutical manufacturers: [1] ESI's commitment not to discriminate between high and low list price versions of the same drug, and [2] delinking administrative fees paid by manufacturers from the list price.... [It] is unclear how ESI and the other PBMs will negotiate rebates for high and low list price drugs going forward."  MORE >>

Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title).
An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above).